Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Changes in Eye Tissue May Enable Early Detection of Brain Diseases

By LabMedica International staff writers
Posted on 11 Oct 2016
Research with mouse models has shown that at least some diseases of the central nervous system (CNS) manifest as pathological changes in the retina of the eye and that these changes may be detected earlier than brain changes. More...
The findings suggest that eye examination could be used for minimally invasive screening for these diseases.

Retina tissue can be considered an integral part of the central nervous system (CNS). During fetal development, it matures from part of the brain and its innervation closely resembles that of the brain. Retinal structure and function can be readily examined with noninvasive or minimally invasive methods, whereas direct brain examination has numerous limitations. If, at least for some brain diseases, the health status of the brain could be indirectly assessed through the eyes, diagnostic screening could become more efficient.

In his PhD project at the University of Eastern Finland at Kuopio (Kuopio, Finland), Dr. Henri Leinonen and colleagues investigated functional abnormalities of the retina using mouse models of human CNS diseases. Electroretinography (ERG) and visual evoked potentials (VEP) were chosen as research techniques, since similar methodology can be applied in both laboratory animals and humans. ERG can precisely track the function of retina using corneal or skin electrodes, whereas VEP measures the function of visual cortex.

These methods were used to test different attributes of vision in 3 distinct genetically engineered mouse models of human CNS diseases. Also, basic life science methods were used to test the correlation between functional abnormalities and the anatomical status of the retina.

Day and color vision -associated retinal dysfunction was found in a mouse model of Huntington´s disease (HD) while the mouse was presymptomatic. Retinal structure remained relatively normal, even in an advanced disease state, although aggregation of toxic mutated huntingtin-protein was widespread in the diseased mouse retina. Although the retinopathy in mice is exaggerated compared to human HD patients, the finding is partly in line with patient data showing impaired color vision but no clear-cut anatomical retinopathy.

In a mouse model of Alzheimer´s disease (AD), the researchers observed abnormality in night vision -associated retinal function. Specifically, rod-mediated inner retinal responses to dim light flashes were faster in diseased mice than in their wild-type controls. The observation may be explained by impaired cholinergic neurotransmission that is also partly causative for the deterioration of memory in AD.

In a mouse model of late infantile neuronal ceroid lipofuscinosis (NCL), a pediatric neurological disease, the researchers described retinal degenerative changes that mimic the characteristic pathology of age-related macular degeneration (AMD). These included impaired function of retinal pigment epithelium and subsequent blindness due to photoreceptor atrophy and death. It has been postulated that the retinal degeneration in human patients progresses similarly.

Adding to the growing body of evidence, the results showed that functional changes of the retina occur in mouse models of three human CNS diseases whose phenotype, age of onset, and pathological mechanism clearly differ from each other. Visual impairment was the fastest progressive symptom in two models tested.

The findings support the idea of eye examinations as potential screening tools for CNS diseases. Development of efficient, safe, and economic screening is imperative since the diagnosis of these diseases is often obtained only in the advanced disease state, when as such satisfactory remedies are poorly effective. Since eye and vision research can be conducted noninvasively, advancement of trials from the preclinical to the clinical phase could be relatively fast.

Dr. Leinonen’s doctoral dissertation, entitled “Electrophysiology of visual pathways as a screening tool for neurodegenerative diseases: evidence from mouse disease models”, is available for download. The findings were published in PLoS One, the Journal of Alzheimer’s Disease, and most recently in the journal Human Molecular Genetics.

Related Links:
University of Eastern Finland


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.